Related Experiment Video
Updated: May 29, 2026
07:42
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition.
Samantha R Adam1, Maxwell Sauder2,3
1Wilfrid Laurier University, Waterloo, ON, Canada.
Skin Therapy Letter
|May 27, 2026
Summary
Zasocitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, shows promise for treating psoriasis and psoriatic arthritis. Its higher selectivity may offer improved safety compared to other TYK2 inhibitors.
Area of Science:
- Immunology
- Pharmacology
Background:
- Psoriasis and psoriatic arthritis are chronic inflammatory conditions.
- Current treatments include biologics and small molecules targeting inflammatory pathways.
- Tyrosine kinase 2 (TYK2) is a key mediator in inflammatory signaling.
Purpose of the Study:
- To review the efficacy, safety, and tolerability of zasocitinib.
- To compare zasocitinib's properties with existing TYK2 inhibitors like deucravacitinib.
Main Methods:
- Review of preclinical and clinical data on zasocitinib.
- Comparative analysis of TYK2 inhibitor selectivity and affinity.
- Assessment of potential off-target effects based on molecular structure and inhibition profiles.
Main Results:
- Zasocitinib demonstrates high selectivity for the TYK2 Janus homology 2 (JH2) domain.
- It exhibits higher target affinity compared to deucravacitinib.
- Minimal inhibition of Janus kinases (JAK) 1, 2, and 3 is anticipated, suggesting reduced off-target effects.
Conclusions:
- Zasocitinib represents a novel, highly selective TYK2 inhibitor.
- Its distinct selectivity profile may translate to a favorable safety and tolerability profile for psoriasis and psoriatic arthritis.
- Further clinical evaluation is warranted to confirm its therapeutic potential.
Related Concept Videos
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...